NCT05629364
A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease
Phase: Phase 2
Role: Lead Sponsor
Start: Mar 15, 2023
Completion: Jan 9, 2024